TNF-α and IL-17

1 paper1 finding

Human trial1

Interventions

1

Umbilical cord-derived mesenchymal stem cells

downin humans1

1 study

Umbilical cord-derived mesenchymal stem cells decrease TNF-α and IL-17 in humans.
“Inflammatory cytokines (TNF-α, IL-17) exhibited declines in MSCs group at 6 months compared to the placebo group (p = 0.034 and 0.033, respectively).”
Human trialpatients with aging frailty; compared with placebo6 months
Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study
Stem cell research & therapy29 Apr 2024

More on Umbilical cord-derived mesenchymal stem cells

Latest

International Immunopharmacology30 Apr

Disease microenvironment preconditioning: An evolving approach to improve therapeutic efficacy of human mesenchymal stromal cells

ReviewInterventions

Stem Cell Research & Therapy29 Apr

Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study

Randomised trial in peopleInterventions